A Systematic Review: Role of Pyloric Dilation in the Management of Gastroparesis.
- 1Department of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada.
- 2Department of Gastroenterology and Gastrointestinal Endoscopy, IRCCS San Raffaele Hospital, Milan, Italy.
- 3Department of Gastroenterology and Hepatology, Academisch Medisch Centrum, Amsterdam, the Netherlands.
Abstract
Background
Gastroparesis (GP) is a motility disorder characterized by pronounced delayed gastric emptying and associated with symptoms. Endoscopic pyloric dilation (PyD) is a minimally invasive option targeting pyloric dysfunction, though efficacy remains variably reported.Aims
This systematic review assessed clinical outcomes and safety of PyD in adults and children with GP not associated with surgical manipulation.Methods
PubMed, Embase, and Scopus were searched through December 2025 for studies evaluating PyD in GP. Post-surgical and non-GP etiologies were excluded. Twelve studies (12 full manuscripts) met inclusion criteria. Data on technique, response rates, and adverse events were extracted.Results
Quality of studies was fair to poor. Symptom improvement with PyD was described in 37%-85% of treated patients. PyD plus botulin toxin efficacy was reported as 50%-80%. Benefits were reported as early as 2 weeks and up to 2 years after intervention. Repeat dilations were occasionally performed with response ranging from 40% to 95% for adults and children. No serious complications were reported. Adverse events were limited to transient pain reported in one study. Variability in technique and outcome definitions limited pooled analyses.Conclusions
Within study quality constraints, PyD may be a low-risk option for symptom relief in select GP patients across all age groups. As there was significant heterogeneity in the data published, well-designed control studies should be performed to evaluate if this efficacy is convincing. Standardized protocols and integration of novel tools such as EndoFLIP are needed to refine patient selection and assess long-term efficacy.
Related
- Refractory Gastroparesis in Ehlers-Danlos Syndrome: Failure of Pyloric-Directed Therapy Despite Normal Pyloric Physiology.
- Gastric Peroral Endoscopic Myotomy in Refractory Gastroparesis: A Narrative Review.
- Physiotherapy Management of Computer Vision Syndrome and Associated Musculoskeletal Dysfunction in Young Adults: A Systematic Review of Evidence-Based Rehabilitation Approaches
- Non-operative management in patients with iatrogenic colorectal perforations: protocol for a systematic review
- Efficacy of whole-body vibration training in the management of patients with COPD: a systematic review and meta-analysis
BibTeX
@article{gupta2026systematic,
title = {{A Systematic Review: Role of Pyloric Dilation in the Management of Gastroparesis.}},
author = {Milli Gupta and Alberto Barchi and Albert J Bredenoord and Gwen M C Masclee},
journal = {Neurogastroenterology and motility},
year = {2026},
month = oct,
doi = {10.1111/nmo.70436},
url = {https://europepmc.org/article/MED/42908102},
note = {CC BY},
}
RIS
TY - JOUR
TI - A Systematic Review: Role of Pyloric Dilation in the Management of Gastroparesis.
AU - Milli Gupta
AU - Alberto Barchi
AU - Albert J Bredenoord
AU - Gwen M C Masclee
PY - 2026
DA - 2026/10/01
JO - Neurogastroenterology and motility
DO - 10.1111/nmo.70436
UR - https://europepmc.org/article/MED/42908102
AB - Background Gastroparesis (GP) is a motility disorder characterized by pronounced delayed gastric emptying and associated with symptoms. Endoscopic pyloric dilation (PyD) is a minimally invasive option targeting pyloric dysfunction, though efficacy remains variably reported.Aims This systematic review assessed clinical outcomes and safety of PyD in adults and children with GP not associated with surgical manipulation.Methods PubMed, Embase, and Scopus were searched through December 2025 for studies evaluating PyD in GP. Post-surgical and non-GP etiologies were excluded. Twelve studies (12 full manuscripts) met inclusion criteria. Data on technique, response rates, and adverse events were extracted.Results Quality of studies was fair to poor. Symptom improvement with PyD was described in 37%-85% of treated patients. PyD plus botulin toxin efficacy was reported as 50%-80%. Benefits were reported as early as 2 weeks and up to 2 years after intervention. Repeat dilations were occasionally performed with response ranging from 40% to 95% for adults and children. No serious complications were reported. Adverse events were limited to transient pain reported in one study. Variability in technique and outcome definitions limited pooled analyses.Conclusions Within study quality constraints, PyD may be a low-risk option for symptom relief in select GP patients across all age groups. As there was significant heterogeneity in the data published, well-designed control studies should be performed to evaluate if this efficacy is convincing. Standardized protocols and integration of novel tools such as EndoFLIP are needed to refine patient selection and assess long-term efficacy.
SN - 1350-1925
SN - 1365-2982
ER -